EUVIMEDEUVIMED entdecken
Multizentrische Studie

Prognostic impact of lung metastasis in patients treated with androgen receptor signaling inhibitors for castration-sensitive prostate cancer: data from the ULTRA-Japan Consortium

Taizo Uchimoto iD, Kensuke Hirosuna, Heima Niigawa, Sho Kakumae, Hirofumi Morinaka, Wataru Fukuokaya, Atsuhiko Yoshizawa, Masanobu Saruta, Saizo Fujimoto, Tsuyoshi Morita, Yutaka Yamamoto, Moritoshi Sakamoto und 18 weitere

Japanese Journal of Clinical Oncology · 2026

DOI: 10.1093/jjco/hyaf161 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Japanese Journal of Clinical Oncology, 2026. Verfasst von Taizo Uchimoto und 29 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Osaka Medical and Pharmaceutical University. 2-7 Daigaku-machi, Takatsuki City, Osaka 569-8686, Japan. Hauptthemen laut MEDLINE: Lung Neoplasms, Androgen Receptor Antagonists, Prostatic Neoplasms, Castration-Resistant. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 19 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Androgen receptor signaling inhibitors (ARSIs) have become the standard treatment for metastatic castration-sensitive prostate cancer (mCSPC). While visceral metastases, including lung metastases (LMs), are considered poor prognostic factors, their impact on clinical outcomes in mCSPC remains unclear. This study aimed to evaluate the prognostic significance of LM in mCSPC patients treated with ARSI-based doublet therapy.

Methods

This retrospective study analyzed a multi-institutional cohort of 453 mCSPC patients treated with ARSIa-based doublet therapy.

Results

The median overall survival (OS) and time to castration resistance (TTCR) were 80 and 41 months, respectively, with a median follow-up of 20 months. The total cohort included 117 patients (25.8%) with LM and 336 patients (74.2%) without LM. LATITUDE high-risk and CHAARTED high-volume criteria classified 380 patients (83.9%) and 356 patients (78.6%), respectively. Although not statistically significant, OS and TTCR showed a trend toward better outcomes in the LM group compared to the non-LM group in LATITUDE high-risk (n = 380: P = .097 for OS and P = .104 for TTCR) and CHAARTED high-volume (n = 356: P = .064 for OS and P = .086 for TTCR). In the propensity score matching cohort (n = 218 and n = 206 for LATITUDE and CHAARTED criteria, respectively), OS and TTCR remained comparable between the LM and non-LM groups.

Conclusions

LM does not appear to be related to OS or TTCR in mCSPC patients treated with ARSI-based doublet therapy, indicating that its prognostic value may need to be reevaluated.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lung NeoplasmsAndrogen Receptor AntagonistsProstatic Neoplasms, Castration-ResistantHumansMaleAgedRetrospective StudiesPrognosisMiddle AgedJapanAged, 80 and overReceptors, Androgen

Stichwörter der Autor:innen

androgen-receptor signaling inhibitorslung metastasismetastatic castration-sensitive prostate canceroverall survivaltime to castration resistance

Substanzen

Androgen Receptor AntagonistsReceptors, Androgen

Autor:innen und Institutionen

  • Department of Urology, Osaka Medical and Pharmaceutical University. 2-7 Daigaku-machi, Takatsuki City, Osaka 569-8686, Japan.
  • Department of Urology, Kawasaki Medical School. 577 Matsushima, Kurashiki City, Okayama 701-0192, Japan.
  • Department of Urology, The Jikei University School of Medicine. 3-25-8 Nishi-shimbashi, Minato-ku, Tokyo 105-8461, Japan.
  • Department of Urology, Fujita-Health University School of Medicine. 1-98 Dengakugakubo, Kutsukake, Toyoake City, Aichi 470-1192, Japan.
  • Department of Urology, Kindai University Faculty of Medicine. 377-2, Oono-higashi, Osakasayama City, Osaka 589-8511, Japan.
  • Department of Urology, Hamamatsu University School of Medicine. 1-20-1 Handayama, Chuo-ku, Hamamatsu, Shizuoka 431-3192, Japan.

ORCID-Profile: Taizo Uchimoto, Fumihiko Urabe, Shunsuke Tsuduki, Kiyoshi Takahara, Takahiro Kimura

Zitieren

APA

Uchimoto, T., Hirosuna, K., Niigawa, H., Kakumae, S., Morinaka, H., Fukuokaya, W., Yoshizawa, A., Saruta, M., Fujimoto, S., Morita, T., Yamamoto, Y., Sakamoto, M., Nishimura, K., Maenosono, R., Tsujino, T., Nishio, K., Yoshikawa, Y., Ichihashi, A., Yamamoto, S., …, & Komura, K. (2026). Prognostic impact of lung metastasis in patients treated with androgen receptor signaling inhibitors for castration-sensitive prostate cancer: data from the ULTRA-Japan Consortium. Japanese Journal of Clinical Oncology. https://doi.org/10.1093/jjco/hyaf161

Vancouver

Uchimoto T, Hirosuna K, Niigawa H, Kakumae S, Morinaka H, Fukuokaya W, et al. Prognostic impact of lung metastasis in patients treated with androgen receptor signaling inhibitors for castration-sensitive prostate cancer: data from the ULTRA-Japan Consortium. Japanese Journal of Clinical Oncology. 2026. doi:10.1093/jjco/hyaf161

BibTeX
@article{Uchimoto2026,
  author = {Uchimoto, Taizo and Hirosuna, Kensuke and Niigawa, Heima and Kakumae, Sho and Morinaka, Hirofumi and Fukuokaya, Wataru and Yoshizawa, Atsuhiko and Saruta, Masanobu and Fujimoto, Saizo and Morita, Tsuyoshi and Yamamoto, Yutaka and Sakamoto, Moritoshi and Nishimura, Kazuki and Maenosono, Ryoichi and Tsujino, Takuya and Nishio, Kyosuke and Yoshikawa, Yuki and Ichihashi, Atsushi and Yamamoto, Shutaro and Iwatani, Kosuke and Urabe, Fumihiko and Mori, Keiichiro and Yanagisawa, Takafumi and Tsuduki, Shunsuke and Takahara, Kiyoshi and Inamoto, Teruo and Fujita, Kazutoshi and Azuma, Haruhito and Kimura, Takahiro and Komura, Kazumasa},
  title = {Prognostic impact of lung metastasis in patients treated with androgen receptor signaling inhibitors for castration-sensitive prostate cancer: data from the ULTRA-Japan Consortium},
  journal = {Japanese Journal of Clinical Oncology},
  year = {2026},
  doi = {10.1093/jjco/hyaf161}
}
Kostenlos starten →